Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 3;147(12):3973-3975.
doi: 10.1093/brain/awae354.

Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression

Wiesje Pelkmans  1   2 , Juan Domingo Gispert  1   2   3   4   5
Affiliations
Editorial

Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression

Wiesje Pelkmans et al. Brain. .

Abstract

This scientific commentary refers to ‘Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline’ by Peretti et al. (https://doi.org/10.1093/brain/awae211).

PubMed Disclaimer

Conflict of interest statement

W.P. reports no competing interests. J.D.G. is currently an AstraZeneca full-time employee and has received research support from GE healthcare, Roche Diagnostics and Hoffmann-La Roche, has given lectures in symposia sponsored by General Electric, Philips, Life Molecular Imaging, Esteve, and Biogen, has served on scientific advisory boards and/or as a consultant for Prothena and Roche Diagnostics, and is the inventor, founder, member of the board of directors and co-owner of BetaScreen.

Figures

Figure 1
Figure 1
Hypothetical course of plasma GFAP concentrations over the course of Alzheimer’s disease progression according to the ‘two-wave’ model of astrocyte reactivity. In the first wave, plasma GFAP rises early in the Alzheimer’s disease (AD) continuum, in association with soluble amyloid-β (Aβ) dyshomeostasis, and may play a key role in fibrillary Aβ aggregation and tau phosphorylation. At later stages of the Alzheimer’s disease pathophysiological cascade, plasma GFAP may influence Aβ-driven aggregation of tau in neurofibrillary tangles. Created in BioRender.com.
See this image and copyright information in PMC

Comment on

References

    1. Lista S, Imbimbo BP, Grasso M, et al. . Tracking neuroinflammatory biomarkers in Alzheimer's disease: A strategy for individualized therapeutic approaches? J Neuroinflammation. 2024;21:187. - PMC - PubMed
    1. Verberk IMW, Laarhuis MB, van den Bosch KA, et al. . Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: A prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2:e87–e95. - PubMed
    1. Benedet AL, Mila-Aloma M, Vrillon A, et al. . Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease Continuum. JAMA Neurol. 2021;78:1471–1483. - PMC - PubMed
    1. Pereira JB, Janelidze S, Smith R, et al. . Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer's disease. Brain. 2021;144:3505–3516. - PMC - PubMed
    1. Pelkmans W, Shekari M, Brugulat-Serrat A, et al. . Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression. Alzheimers Dement. 2024;20:483–493. - PMC - PubMed